Multiple Endocrine Neoplasia Type 1 (MEN1)
Table of Contents
Overview
Multiple Endocrine Neoplasia Type 1 (MEN1), also historically called Wermer syndrome after the physician who first described familial clustering of pituitary tumors with peptic ulcers in 1954, is an autosomal dominant hereditary tumor syndrome defined by the development of tumors in at least two of three classic endocrine sites: the parathyroid glands, the pancreatic and gastrointestinal neuroendocrine cells, and the anterior pituitary gland. This constellation is captured in the mnemonic of the three P's — parathyroid, pancreatic/gastrointestinal (GI) neuroendocrine tumors (pNETs), and pituitary.
MEN1 is rare but clinically important. Its estimated prevalence is 2 per 100,000 people (about 1 in 50,000), affecting men and women equally. Penetrance is near complete by age 50, meaning that nearly all individuals who carry a germline MEN1 mutation will develop at least one component tumor if they live into middle age. The condition can present in childhood or adolescence — hypercalcemia due to parathyroid hyperplasia in a teenager is one of the classic clinical clues that leads to MEN1 genetic evaluation.
The practical consequence of recognizing MEN1 is significant. Unlike sporadic endocrine tumors, MEN1-associated tumors are typically multiple, bilateral, and prone to recurrence after surgery. Treatment strategies and surveillance protocols differ substantially from those used for sporadic counterparts. In practice, identifying one MEN1 component tumor leads to systematic screening for the others, and confirming a germline MEN1 mutation leads to cascade testing among first-degree relatives.
Genetics and Pathogenesis
MEN1 is caused by germline loss-of-function mutations in the MEN1 tumor suppressor gene located on chromosome 11q13. This gene encodes menin, a 610-amino-acid nuclear protein that functions as a scaffold protein involved in histone modification and chromatin remodeling. Menin interacts with histone methyltransferase complexes (particularly the MLL/SET1 complex responsible for H3K4 trimethylation) to regulate transcription of genes controlling cell proliferation, apoptosis, and DNA repair. Loss of menin disrupts this chromatin-regulatory function, allowing uncontrolled proliferation of susceptible endocrine cells.
Tumor development in MEN1 follows the classic Knudson two-hit model for tumor suppressor genes. Affected individuals inherit one defective copy of MEN1 in every cell (the first hit). Tumorigenesis occurs when a somatic event — a point mutation, deletion, or loss of heterozygosity — inactivates the remaining wild-type allele in a susceptible endocrine cell (the second hit). The resulting cell, now with no functional menin, loses growth control and gives rise to a tumor. Because somatic second hits are random and independent events occurring in trillions of cells over a lifetime, multiple tumors arise at different times and in different endocrine glands — explaining the characteristic multiplicity and metachronous (asynchronous) timing of MEN1 neoplasms.
More than 1,300 distinct germline MEN1 mutations have been catalogued. Frameshift mutations (due to small insertions or deletions) and nonsense mutations (premature stop codons) are the most common classes, together accounting for roughly 75% of identified mutations; missense mutations, splice-site mutations, and large deletions make up the remainder. Germline MEN1 mutations are identified by sequencing in approximately 70–90% of patients who fulfill clinical diagnostic criteria. The remaining 10–30% of clinical MEN1 cases are either attributable to mutations in regulatory regions not captured by standard coding-sequence analysis, somatic mosaicism, or mutations in other genes such as CDKN1B (encoding p27, associated with the rarer MEN4 syndrome). Approximately 10% of MEN1 mutations arise de novo, meaning affected individuals have no family history.
The Three P's — Classic Triad
Endocrinologists often teach MEN1 using the mnemonic of the Three P's: Parathyroid, Pituitary, and Pancreas (or more precisely, pancreatic-duodenal neuroendocrine tumors). These three sites are affected in 95%, 30–40%, and 30–75% of patients respectively over a lifetime of follow-up, depending on the surveillance intensity and patient age.
The parathyroid glands are nearly universally involved and are typically the first manifestation to appear, usually in the second or third decade of life. The pancreatic and duodenal neuroendocrine tumors (pNETs) tend to emerge in the third or fourth decade and carry the greatest risk of malignancy. Pituitary adenomas are often discovered on surveillance imaging; prolactinomas predominate and are frequently manageable with medication alone.
What distinguishes MEN1-associated tumors from their sporadic counterparts is the tendency toward multifocality and bilaterality. A patient with sporadic primary hyperparathyroidism typically has a single enlarged parathyroid gland; a MEN1 patient has all four glands hyperplastic. A sporadic insulinoma is virtually always solitary; MEN1 patients may have dozens of pNETs scattered through the pancreas and duodenal wall simultaneously. This fundamental difference drives the distinct surgical and surveillance strategies required in MEN1.
Parathyroid Disease — the Earliest and Most Penetrant Feature
Primary hyperparathyroidism (PHPT) due to parathyroid hyperplasia is the most common and earliest manifestation of MEN1, occurring in 90–100% of mutation carriers over a lifetime. It is typically the first endocrine abnormality to appear, often becoming biochemically detectable in the second or third decade of life. The diagnosis of primary hyperparathyroidism in a patient younger than 30 — and especially in a teenager — is a strong clinical signal for MEN1 evaluation even in the absence of a family history.
The parathyroid disease of MEN1 differs fundamentally from sporadic PHPT in its pathology. In sporadic PHPT, a single parathyroid adenoma is responsible in 85–90% of cases. In MEN1-associated PHPT, all four parathyroid glands are typically hyperplastic — a multigland process reflecting the widespread first-hit predisposition carried in every cell. This multigland nature has critical surgical implications: focused minimally invasive parathyroidectomy (which is highly effective for sporadic single-gland adenoma) is generally inappropriate for MEN1, where removing only one abnormal gland leaves three others destined to develop autonomous secretion.
The clinical consequences of MEN1-associated PHPT are identical to those of sporadic hypercalcemia: nephrolithiasis (kidney stones, occurring in 15–20% of MEN1 patients with PHPT), osteoporosis with increased fracture risk, and the nonspecific symptoms of hypercalcemia (fatigue, cognitive dulling, constipation, polydipsia, polyuria). Severe symptomatic hypercalcemia (serum calcium above 12 mg/dL) is less common than in sporadic PHPT. Of note, hypercalcemia from MEN1-associated PHPT can complicate management of gastrinoma (Zollinger-Ellison syndrome): hypercalcemia itself stimulates gastrin release, worsening the acid-hypersecretory state. Treating PHPT may therefore partially ameliorate ZES symptoms.
Surgical management favors subtotal parathyroidectomy (removal of 3.5 glands, leaving a well-vascularized remnant of approximately 50 mg) or total parathyroidectomy with autotransplantation of parathyroid tissue into a forearm muscle, which allows easy re-access if the remnant becomes overactive. Both approaches have higher recurrence rates than sporadic PHPT surgery — approximately 50% of patients develop recurrent hypercalcemia within 10–12 years — reflecting continued growth pressure on remaining parathyroid tissue under MEN1 genetic predisposition.
Pancreatic and Gastrointestinal Neuroendocrine Tumors (pNETs)
Pancreatic and gastrointestinal neuroendocrine tumors occur in 60–70% of MEN1 patients and represent the leading cause of MEN1-related mortality. Unlike sporadic pNETs (which are typically solitary), MEN1-associated pNETs are characteristically multiple, small, and distributed throughout the pancreatic head, body, and tail. Non-functional pNETs — tumors that do not secrete a clinically detectable hormonal syndrome — are actually the most prevalent pancreatic tumors in MEN1, found in 40–80% of patients at autopsy or detailed imaging. Their clinical significance lies in malignant potential: large non-functional pNETs (greater than 2–3 cm) carry significant risk of hepatic metastasis and are a major driver of disease-specific mortality.
Gastrinoma and Zollinger-Ellison Syndrome — Gastrinoma is the most common functional pNET in MEN1, occurring in roughly 40% of patients and producing the dramatic Zollinger-Ellison syndrome (ZES): hypergastrinemia drives massive gastric acid hypersecretion, causing multiple peptic ulcers (often in atypical locations such as the distal duodenum or jejunum), diarrhea (from mucosal injury and bile acid inactivation), and acid-induced esophagitis. A critical anatomical nuance: despite the name "pancreatic gastrinoma," the majority of MEN1-associated gastrinomas actually arise in the wall of the duodenum (the submucosal gastrinoma triangle), not in the pancreas itself. They are typically small (less than 1 cm), multiple, and difficult to localize. Somatostatin receptor scintigraphy (indium-111 pentetreotide scintigraphy) or 68Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) is superior to computed tomography for detecting small gastrinomas. Biochemically, fasting serum gastrin above 1,000 pg/mL (with gastric pH below 2) is diagnostic of ZES; the secretin stimulation test (paradoxical gastrin rise of greater than 200 pg/mL after secretin injection) confirms the diagnosis in ambiguous cases. Medical management with high-dose proton pump inhibitors (often 60–80 mg of omeprazole or equivalent per day) effectively controls acid hypersecretion in most patients; surgical cure is far less achievable in MEN1-associated than in sporadic ZES due to multiplicity of tumors.
Insulinoma — Insulinoma occurs in approximately 10% of MEN1 patients and is the most common cause of hypoglycemia in this population. It produces autonomous insulin secretion, resulting in symptomatic fasting hypoglycemia. Whipple's triad — symptoms of hypoglycemia, documented low blood glucose (below 55 mg/dL), and relief of symptoms with glucose administration — remains the clinical cornerstone of diagnosis. Biochemically, elevated fasting insulin, C-peptide, and proinsulin in the setting of hypoglycemia confirm the diagnosis, while a negative sulfonylurea screen excludes factitious hypoglycemia. MEN1-associated insulinomas are often multiple. Surgical resection (distal pancreatectomy with or without enucleation of additional tumors in the pancreatic head) is the treatment of choice. Medical bridging with diazoxide or somatostatin analogs may be needed preoperatively or for inoperable cases.
Other Functional pNETs — VIPoma (vasoactive intestinal peptide-secreting tumor) causes profuse watery diarrhea, hypokalemia, and achlorhydria (Verner-Morrison syndrome, also called WDHA syndrome for watery diarrhea, hypokalemia and achlorhydria). Glucagonoma produces the classic glucagonoma syndrome: necrolytic migratory erythema (a distinctive skin rash), diabetes mellitus, weight loss, anemia, and venous thrombosis. PPoma (pancreatic polypeptide-secreting tumor) is technically non-functional in that elevated pancreatic polypeptide does not cause a clinical syndrome but serves as a useful tumor marker. These rarer functional pNETs each have distinct clinical and biochemical signatures that allow diagnosis before imaging localizes the culprit tumor.
Pituitary Adenomas
Pituitary adenomas occur in 30–40% of MEN1 patients. Although they are the third most common MEN1 feature, they are often among the most clinically impactful because they can cause both hormonal hypersecretion syndromes and mass effect on surrounding structures. MEN1-associated pituitary adenomas tend to be larger (macroadenomas) and more aggressive than sporadic counterparts, with a higher rate of invasion into surrounding bone and cavernous sinus.
Prolactinoma is the most common pituitary adenoma subtype in MEN1, accounting for approximately 60% of pituitary tumors in this setting. Excess prolactin causes hypogonadotropic hypogonadism: in women, amenorrhea, galactorrhea, and infertility; in men, decreased libido, erectile dysfunction, infertility, and gynecomastia. The first-line treatment is a dopamine agonist — cabergoline (preferred over bromocriptine due to superior efficacy and tolerability) — which suppresses prolactin secretion and often causes significant tumor shrinkage. Surgical transsphenoidal resection is reserved for dopamine agonist-resistant or intolerant cases.
Growth hormone (GH)-secreting adenomas (somatotropinomas) cause acromegaly in adults (or gigantism if growth plates are still open in adolescents): coarsening of facial features, acral enlargement (hands and feet), hyperhidrosis, arthropathy, sleep apnea, cardiomegaly, and glucose intolerance. Diagnosis rests on failure of GH suppression during an oral glucose tolerance test (GH nadir above 0.4 ng/mL) combined with elevated insulin-like growth factor 1 (IGF-1) adjusted for age and sex. Transsphenoidal surgery is first-line; somatostatin analogs (long-acting octreotide, long-acting lanreotide) and the GH receptor antagonist pegvisomant are used for residual or recurrent disease.
Adrenocorticotropic hormone-secreting adenomas (corticotropinomas) cause Cushing's disease, the most severe hormonal syndrome arising from the pituitary in MEN1. Clinical features include central obesity, purple striae, proximal myopathy, hypertension, hyperglycemia, easy bruising, and osteoporosis. Diagnosis requires demonstration of adrenocorticotropic hormone-dependent hypercortisolism (elevated late-night salivary cortisol, 24-hour urine free cortisol, and failure of suppression with low-dose dexamethasone), followed by petrosal sinus sampling when needed to confirm pituitary origin. Transsphenoidal resection is the treatment of choice.
Non-functional pituitary adenomas do not cause hormonal syndromes but can produce mass effect: visual field deficits (classically bitemporal hemianopia from compression of the optic chiasm), headache, and hypopituitarism from compression of normal pituitary tissue. Transsphenoidal resection is indicated for progressive visual compromise or tumor growth.
Other Manifestations
MEN1 produces a range of tumors and lesions beyond the classic triad that matter both for their independent clinical impact and as diagnostic clues when the classic triad is incomplete.
Adrenal Cortical Adenomas — Adrenal cortical tumors (adenomas or hyperplasia) develop in about 40% of people with MEN1 by age 40, usually detected incidentally on abdominal imaging performed for pNET surveillance. The great majority are non-functional (not secreting cortisol, aldosterone, or androgens in excess), and the adrenal lesions of MEN1 are rarely pheochromocytomas (under 1%; pheochromocytoma is the adrenal hallmark of MEN2). Functional adrenal adenomas causing Cushing's syndrome or hyperaldosteronism do occur in MEN1 but are uncommon. Management follows standard incidentaloma guidelines: biochemical evaluation for subclinical hormonal excess and serial size monitoring, with adrenalectomy reserved for functional tumors or lesions showing worrisome growth or size above 4–6 cm.
Foregut Carcinoids — Carcinoid tumors arising from foregut-derived tissue represent a clinically important and potentially life-threatening non-classic MEN1 manifestation. Bronchial carcinoids (in the lung) are more common in women with MEN1, while thymic carcinoids are predominantly found in men. Thymic carcinoids deserve particular emphasis: they are more aggressive than bronchial carcinoids, can metastasize to lymph nodes and distant organs, and a 2019 review lists heavy smoking as a possible risk factor for them. In the French-Belgian registry of 761 MEN1 patients, 21 had thymic tumors; all but one were men, the youngest was 16, the average age at diagnosis was 42.7 years, and only 36.1% were alive 10 years later. Five of them had had their thymus removed beforehand as a preventive step, without success. The 2012 Endocrine Society guideline's surveillance is chest computed tomography or magnetic resonance imaging every 1–2 years from age 15. Resection is indicated when thymic or bronchial carcinoids are detected. Unlike carcinoids in the general population, MEN1-associated thymic carcinoids rarely produce the carcinoid syndrome (flushing, diarrhea) and more often present as asymptomatic chest masses or incidental findings.
Cutaneous Manifestations — Skin lesions are common and characteristic in MEN1: by age 40, lipomas, facial angiofibromas and collagenomas are found in about 30%, 85% and 70% of patients respectively. They are strong clues rather than proof of the syndrome — in one study of people with gastrinoma, at least 3 angiofibromas plus any collagenoma identified MEN1 with a sensitivity of 75% and a specificity of 95%. The three characteristic lesions are: (1) multiple facial angiofibromas — small, flesh-colored or pink papules on the nose and upper lip indistinguishable from the angiofibromas of tuberous sclerosis; (2) collagenomas — flesh-colored connective tissue nevi, typically on the trunk; and (3) lipomas — soft subcutaneous fat deposits that may be multiple. These cutaneous findings are clinically benign but their presence in a young patient with hypercalcemia or peptic ulcer disease is a recognized clue to MEN1 and a reason for genetic evaluation. Dermatologists occasionally identify MEN1 before endocrinologists are involved.
Diagnosis and Surveillance
The clinical diagnosis of MEN1 is established when a patient develops two or more of the three primary component tumors (parathyroid, pNET, pituitary). A patient with one component tumor and a first-degree relative with MEN1 also meets diagnostic criteria. Genetic MEN1 (or presymptomatic MEN1) is defined by the identification of a germline MEN1 mutation in an individual who may not yet have developed clinical tumors.
Germline MEN1 gene sequencing identifies a pathogenic mutation in approximately 70–90% of clinically diagnosed cases. Over 1,300 distinct mutations have been catalogued, most causing loss of function through frameshift or nonsense mechanisms. When standard sequencing is negative in a patient with a strong clinical phenotype, large deletion/duplication analysis (using multiplex ligation-dependent probe amplification (MLPA) or array comparative genomic hybridization (array CGH)) can identify whole-exon deletions that coding-sequence analysis misses. Negative genetic testing does not rule out MEN1 in patients fulfilling clinical criteria.
Biochemical Surveillance — the 2012 Endocrine Society guideline sets out a surveillance scheme for people with MEN1 and mutation carriers that starts at age 5 and continues for life, with yearly blood tests that begin at different ages: fasting glucose and insulin (insulinoma) from age 5; prolactin and insulin-like growth factor 1 (pituitary) from age 5; serum calcium and parathyroid hormone (PTH) (parathyroid) from age 8; and fasting serum gastrin (gastrinoma, checked off proton pump inhibitors (PPIs) if safe) from age 20. Chromogranin A serves as a general neuroendocrine tumor marker but lacks specificity.
Imaging Surveillance complements biochemical monitoring. In the same guideline, pituitary magnetic resonance imaging (MRI) is done every 3 years from age 5 (and every 1–2 years after pituitary adenoma detection); pancreatic imaging by MRI, computed tomography (CT) or endoscopic ultrasound is done every year from before age 10, because large pancreatic tumors can develop between 10 and 20 years of age; and chest CT or MRI (for bronchial and thymic carcinoids) is done every 1–2 years from age 15. Functional imaging with 68Ga-DOTATATE positron emission tomography/computed tomography has largely supplanted conventional somatostatin receptor scintigraphy for detection of small pNETs and carcinoids, offering superior sensitivity and spatial resolution.
Treatment
Treatment of MEN1 is individualized and tumor-specific, guided by the hormone secreted, tumor size, malignant potential, and the patient's overall tumor burden.
Parathyroid Disease — Surgical intervention is preferred for MEN1-associated PHPT when calcium is above 1 mg/dL above the upper limit of normal, when nephrolithiasis or osteoporosis is present, or when the patient is symptomatic. Bilateral neck exploration is required to assess all four glands. Subtotal parathyroidectomy (removing 3.5 glands and leaving a well-vascularized 50 mg remnant in the neck) and total parathyroidectomy with heterotopic autotransplantation into the brachioradialis muscle of the non-dominant forearm are the two accepted approaches. Both carry higher recurrence rates than sporadic PHPT surgery. Cinacalcet, a calcimimetic that allosterically activates the calcium-sensing receptor (CaSR) on parathyroid cells, can reduce calcium in patients who decline surgery or have recurrent disease, but does not address tumor growth.
Gastrinoma and Zollinger-Ellison Syndrome — High-dose proton pump inhibitor therapy (omeprazole 60–80 mg/day or equivalent in divided doses, titrated to achieve gastric pH above 4) effectively controls acid hypersecretion and heals peptic ulcers in the great majority of patients. Proton pump inhibitors have transformed the prognosis of ZES: patients who previously died of intractable peptic ulcer disease now die of malignant gastrinoma, if at all. Surgical resection of MEN1-associated gastrinoma is complex: because most lesions are multiple and duodenal, biochemical cure rates with surgery are far lower than for sporadic gastrinoma, and the procedure carries perioperative risk. Many centers reserve surgery for large (greater than 2 cm) or growing tumors with malignant potential. Somatostatin analogs (octreotide, lanreotide) are used for gastric acid control refractory to proton pump inhibitors and for anti-proliferative management of metastatic disease.
Insulinoma — Surgical resection is definitive. Distal pancreatectomy with enucleation of identifiable tumors in the pancreatic head is the usual approach. Preoperative endoscopic ultrasound, combined with 68Ga-DOTATATE positron emission tomography, improves tumor localization. Intraoperative ultrasound is invaluable for identifying small lesions invisible on the pancreatic surface. Diazoxide (inhibits insulin secretion via potassium channel opening) and somatostatin analogs control hypoglycemia in patients awaiting surgery or with inoperable disease.
Non-functional pNETs — Tumors above 2 cm carry significant malignant potential and are generally resected. Tumors below 2 cm are managed with watchful waiting and interval imaging given the high prevalence of small non-functional pNETs in MEN1 and the risks of repeated pancreatic surgery. Everolimus (mechanistic target of rapamycin (mTOR) inhibitor) and sunitinib (tyrosine kinase inhibitor) are approved for progressive, unresectable, or metastatic pNETs and are options when surgery is not feasible.
Newer Drug and Radiation Treatments for Advanced Tumors — These trials enrolled people with advanced neuroendocrine tumors in general, not only people with MEN1. In the CABINET trial (published 2024–2025), cabozantinib 60 mg a day was compared with placebo in 95 people whose pancreatic neuroendocrine tumors were growing after earlier treatment: the median time before the tumors grew again was 13.8 months versus 4.4 months on placebo (hazard ratio 0.23), and the tumors shrank in 19%. Serious (grade 3 or higher) side effects affected 62–65% of people on cabozantinib, against 23–27% on placebo, most often high blood pressure, tiredness, diarrhea and blood clots. The US drug label now includes previously treated, advanced, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older. In the NETTER-2 trial (2024), 226 people with newly diagnosed, advanced grade 2–3 gut and pancreatic neuroendocrine tumors received either lutetium-177 dotatate (a radioactive drug that seeks out the tumors' somatostatin receptors, also called peptide receptor radionuclide therapy) plus long-acting octreotide, or high-dose long-acting octreotide alone. The median time before tumor growth was 22.8 months with lutetium-177 dotatate against 8.5 months without it (hazard ratio 0.276).
Pituitary Adenomas — Prolactinoma is managed first with dopamine agonists (cabergoline 0.5–3.0 mg weekly; bromocriptine as alternative). GH-secreting adenomas are treated with transsphenoidal surgery as the primary approach, followed by somatostatin analogs (long-acting octreotide or long-acting lanreotide) for residual disease, with pegvisomant (GH receptor antagonist) added for inadequate insulin-like growth factor 1 normalization. Cushing's disease from adrenocorticotropic hormone-secreting adenomas requires transsphenoidal resection; persistent or recurrent hypercortisolism is managed with bilateral adrenalectomy, steroidogenesis inhibitors (metyrapone, ketoconazole), or pasireotide. Non-functional pituitary macroadenomas are resected when they cause visual compromise, and monitored with serial magnetic resonance imaging when small and asymptomatic.
Prognosis and Genetic Counseling
The prognosis of MEN1 has improved substantially with modern biochemical surveillance, which detects tumors at smaller sizes before malignant transformation or hormone hypersecretion cause irreversible organ damage. Nevertheless, MEN1 remains associated with reduced life expectancy compared to the general population. Disease-specific mortality is driven primarily by malignant pNETs (particularly non-functional pNETs with hepatic metastasis and thymic carcinoids) rather than by the hormonally active tumors, which are generally detectable and treatable. Population registry data from France and other countries indicate a median age of death in MEN1 patients of approximately 55–60 years, compared to 70+ years in age-matched controls, though more recent cohorts managed with systematic surveillance are doing better.
The French-Belgian registry of 758 MEN1 patients (median follow-up 6.3 years) measured which tumors raised the risk of death after adjusting for age, sex and time of diagnosis: thymic tumors (hazard ratio 4.64), glucagonomas, VIPomas and somatostatinomas together (hazard ratio 4.29), non-functioning pancreatic tumors (hazard ratio 3.43) and gastrinoma (hazard ratio 1.89). Pituitary tumors, insulinomas and bronchial tumors did not raise the risk of death. Women, people with a family history of MEN1 and people diagnosed more recently had a lower risk. Most deaths were caused by MEN1 itself — 76.8% before 1990 and 71.4% after.
Thymic carcinoids, found mostly in men with MEN1, are a particularly aggressive cause of death. A 2019 review lists heavy smoking as a possible risk factor for them, which makes tobacco one of the few MEN1 risks that a person can change.
Genetic counseling is an essential component of MEN1 care. The condition is autosomal dominant with near-complete penetrance, meaning that each first-degree relative of an affected individual has a 50% probability of carrying the germline mutation. The 2012 Endocrine Society guideline notes that first-degree relatives can often be identified by MEN1 mutation testing, and testing is also done in children, because parathyroid disease can manifest in the first decade and the guideline's surveillance for mutation carriers starts at age 5. Prenatal testing and preimplantation genetic diagnosis are available options for affected individuals who wish to prevent transmission. Psychological support and peer connections through patient advocacy organizations (such as the Association for Multiple Endocrine Neoplasia Disorders, AMEND) are important adjuncts to clinical management.
Key Research Papers
- Chandrasekharappa SC et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997. — PubMed PMID: 9103196
- Thakker RV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012. — PubMed PMID: 22723327
- Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014. — PubMed PMID: 23933118
- Lemmens I et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997. — PubMed PMID: 9215690
- Alrezk R et al. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 2017. — PubMed PMID: 28824003
- Falconi M et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012. — PubMed PMID: 22261872
- Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): An update and the significance of early genetic and clinical diagnosis. Front Endocrinol 2019. — PubMed PMID: 31263451
- Marini F et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006. — PubMed PMID: 17014705
- Goudet P et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 patients. World J Surg 2009. — PubMed PMID: 19294466
- Goudet P et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010. — PubMed PMID: 19949948
- Chan JA et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 2025. — PubMed PMID: 39282913
- Singh S et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 2024. — PubMed PMID: 38851203